{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:32:39Z","timestamp":1762507959010,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.msard.2019.101893","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T03:27:13Z","timestamp":1576207633000},"page":"101893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab"],"prefix":"10.1016","volume":"39","author":[{"given":"Tjalf","family":"Ziemssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Tackenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Lassek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Ettle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2019.101893_bib0001","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","article-title":"Classifying PML risk with disease modifying therapies","volume":"12","author":"Berger","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2019.101893_bib0002","series-title":"Presented at the 7th joint ECTRIMS-ACTRIMS Meeting","article-title":"Effectiveness and safety of fingolimod in patients with multiple sclerosis switched from natalizumab: results from TRANSITION\u00a0\u2212\u00a0a 2-year observational study [poster]","author":"Butzkueven","year":"2017"},{"issue":"6","key":"10.1016\/j.msard.2019.101893_bib0003","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2019.101893_bib0004","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/ene.12487","article-title":"No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation","volume":"22","author":"Capobianco","year":"2015","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2019.101893_bib0005","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jamaneurol.2014.1200","article-title":"Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)","volume":"71","author":"Clerico","year":"2014","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2019.101893_bib0006","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2019.101893_bib0007","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jamaneurol.2013.6240","article-title":"Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study","volume":"71","author":"Cohen","year":"2014","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2019.101893_bib0008","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1352458514549404","article-title":"Relapses in patients treated with fingolimod after previous exposure to natalizumab","volume":"21","author":"Comi","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101893_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418791103","article-title":"Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod","volume":"11","author":"Diem","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2019.101893_bib0010","unstructured":"European Medicines Agency, 2018. EMA confirms recommendations to minimise risk of brain infection PML with Tysabri. Available from: https:\/\/www.ema.europa.eu\/news\/ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri (Accessed 22 November 2018)."},{"key":"10.1016\/j.msard.2019.101893_bib0011","unstructured":"Gilenya E.P.A.R., 2018. Gilenya summary of product charactierstics. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002202\/WC500104528.pdf (Accessed 25 April 2018)."},{"issue":"14","key":"10.1016\/j.msard.2019.101893_bib0012","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1212\/WNL.0000000000000296","article-title":"Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes","volume":"82","author":"Giovannoni","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101893_bib0013","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.2147\/DDDT.S137572","article-title":"Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis","volume":"11","author":"Guarnera","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"issue":"11","key":"10.1016\/j.msard.2019.101893_bib0014","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1007\/s00415-019-09464-0","article-title":"Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry","volume":"266","author":"Guger","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.101893_bib0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/TCRM.S41552","article-title":"Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?","volume":"9","author":"Havla","year":"2013","journal-title":"Ther. Clin. Risk Manag."},{"issue":"5","key":"10.1016\/j.msard.2019.101893_bib0016","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00415-012-6808-8","article-title":"Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis","volume":"260","author":"Havla","year":"2013","journal-title":"J. Neurol."},{"issue":"13","key":"10.1016\/j.msard.2019.101893_bib0017","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1177\/1352458514533398","article-title":"Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod","volume":"20","author":"Hoepner","year":"2014","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2019.101893_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176174","article-title":"The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: an observational study","volume":"12","author":"Izquierdo","year":"2017","journal-title":"PLoS ONE"},{"issue":"14","key":"10.1016\/j.msard.2019.101893_bib0019","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1212\/WNL.0000000000000283","article-title":"Fingolimod after natalizumab and the risk of short-term relapse","volume":"82","author":"Jokubaitis","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2019.101893_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2019.101893_bib0021","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2019.101893_bib0023","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2147\/PPA.S20791","article-title":"An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations","volume":"9","author":"Kornek","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"10.1016\/j.msard.2019.101893_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174858","article-title":"Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?","volume":"12","author":"Kramer","year":"2017","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.msard.2019.101893_bib0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10072-016-2701-z","article-title":"Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy","volume":"38","author":"Laroni","year":"2017","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2019.101893_bib0026","article-title":"Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients","author":"Leurs","year":"2017","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2019.101893_bib0027","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40120-015-0038-9","article-title":"Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers","volume":"4","author":"Lo Re","year":"2015","journal-title":"Neurol. Ther."},{"issue":"8 Suppl 3","key":"10.1016\/j.msard.2019.101893_bib0028","first-page":"S20","article-title":"Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis","volume":"76","author":"Mehling","year":"2011","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.msard.2019.101893_bib0029","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1177\/1352458515570768","article-title":"Natalizumab discontinuation in patients with multiple sclerosis: profiling risk and benefits at therapeutic crossroads","volume":"21","author":"Prosperini","year":"2015","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2019.101893_bib0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/ane.12250","article-title":"What to expect after natalizumab cessation in a real-life setting","volume":"130","author":"Salhofer-Polanyi","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.msard.2019.101893_bib0031","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12974-016-0635-2","article-title":"New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies","volume":"13","author":"Sehr","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"2","key":"10.1016\/j.msard.2019.101893_bib0032","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis - insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2019.101893_bib0022","unstructured":"Kompetenznetz Multiple Sklerose, 2018. Qualitaetshandbuch MS \/ NMOSD: empfehlungen zur therapie der Multiple Sklerose\/Neuromyelitis-optica-Spektrum-Erkrankungen fuer Aerzte. Available from: https:\/\/www.kompetenznetz-multiplesklerose.de\/fachinformationen\/qualitaetshandbuch\/ (Accessed 3 December 2018). German."},{"key":"10.1016\/j.msard.2019.101893_bib0033","unstructured":"Tysabri E.P.A.R., 2018. Tysabri summary of product charactierstics. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000603\/WC500044686.pdf (Accessed 25 April 2018)."},{"issue":"5","key":"10.1016\/j.msard.2019.101893_bib0034","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.msard.2015.07.007","article-title":"Optimizing therapy early in multiple sclerosis: an evidence-based view","volume":"4","author":"Ziemssen","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2019.101893_bib0035","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","article-title":"Optimizing treatment success in multiple sclerosis","volume":"263","author":"Ziemssen","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.101893_bib0036","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12883-015-0342-0","article-title":"The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice","volume":"15","author":"Ziemssen","year":"2015","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/j.msard.2019.101893_bib0037","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1212\/NXI.0000000000000548","article-title":"Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany","volume":"6","author":"Ziemssen","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2019.101893_bib0038","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s13311-017-0595-y","article-title":"Clinical and demographic profile of patients receiving fingolimod in clinical practice in Germany and the benefit-risk profile of fingolimod after 1 year of treatment: initial results from the observational, noninterventional study PANGAEA","volume":"15","author":"Ziemssen","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"13","key":"10.1016\/j.msard.2019.101893_bib0039","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1177\/1352458516629769","article-title":"A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients","volume":"22","author":"Zivadinov","year":"2016","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819309642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819309642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:49:23Z","timestamp":1761900563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819309642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":39,"alternative-id":["S2211034819309642"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.101893","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.101893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101893"}}